<DOC>
	<DOCNO>NCT02520427</DOCNO>
	<brief_summary>The purpose First-in-Human Phase 1 study determine AMG 330 give continuous IV infusion safe tolerable adult subject relapsed/refractory Acute Myeloid Leukemia , determine maximum tolerate dose and/or biologically active dose . The study conduct multiple site test increase dos AMG 330 . The safety subject monitor intensive assessment vital sign , electrocardiogram , physical examination , laboratory test .</brief_summary>
	<brief_title>A Phase 1 Study AMG 330 Subjects With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Inclusion criterion : Informed consent provide 18 year old AML define WHO Classification persist recur follow one treatment course except promyelocytic leukemia ( APML ) except AML secondary prior myelodysplastic syndrome . For Germany : AML define WHO Classification either persisting/refractory least 2 primary induction course ( ie , response least 2 prior chemotherapy cycle ) recur achieve initial response chemotherapy except promyelocytic leukemia ( APML ) except AML secondary prior myelodysplastic syndrome . More 5 % blast bone marrow ECOG Performance Status ≤ 2 Adequate renal hepatic function Exclusion criterion : Active extramedullary AML testes central nervous system ( CNS ) Known hypersensitivity immunoglobulins component IP formulation Prior malignancy ( situ cancer ) unless treat curative intent without evidence disease &gt; 2 year screen Autologous HSCT within six week prior start AMG 330 treatment Allogeneic HSCT within three month prior start AMG 330 treatment History evidence cardiovascular risk History arterial thrombosis ( eg , stroke transient ischemic attack ) past 3 month Infection require intravenous antibiotic within 1 week study enrollment ( day 1 ) Known positiv test HIV Positive Hepatitis B Positive Hepatitis C chronic Hepatitis C Unresolved toxicity prior antitumor therapy , define resolve CTCAE , version 4.0 grade 1 Antitumor therapy ( chemotherapy , antibody therapy , moleculartargeted therapy , retinoid therapy , investigational agent ) within 14 day 5 halflives day 1 Treatment systemic immune modulators 2 week enrollment ( day 1 ) All herbal medicine ( eg , St. John 's wort ) , vitamin , supplement consume subject within 30 day prior receive first dose AMG 330 For subject expansion cohort : Ingestion food drink contain grapefruit Seville oranges , St. John´s wort , within 7 day prior receive first dose AMG 330 Prior treatment monoclonal antibody chimeric antigen receptor T cell infusion treatment AML Prior participation investigational study within 21 day study day 1 Major surgery within 28 day study day 1 exception biopsy long line insertion White blood cell ( WBC ) &gt; 15,000 cells/mcL screen History evidence clinically significant disorder , condition disease , opinion investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedures completion Men woman reproductive potential unwilling practice highly effective method ( ) birth control study 1 week ( woman ) 12 week ( men ) Women lactating/breastfeeding plan breastfeed sudy 1 week receive last dose study drug Women positive pregnancy test Women plan become pregnant study 1 week receive last dose study drug Subjects likely available complete protocolrequired study visit procedure , and/or comply require study procedure best subject investigator 's knowledge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Oncology/Hematology</keyword>
	<keyword>Relapsed/Refractory AML</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>